From Self-sufficiency
Jump to: navigation, search
File:Pazopanib structure.svg
Systematic (IUPAC) name
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
  • US: D (Evidence of risk)
Routes of
Legal status
Legal status
Pharmacokinetic data
Protein binding >99%
Metabolism Hepatic (CYP3A4, 1A2 and 2C8-mediated)
Biological half-life 31 hours (mean)
Excretion Mostly fecal
CAS Number 444731-52-6
ATC code L01XE11 (WHO)
PubChem CID 11525740
ChemSpider 8289501
Chemical data
Formula C21H23N7O2S
Molar mass 437.517 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma by the U.S. Food and Drug Administration.[1] Pazopanib may also be active in ovarian cancer[2] and soft tissue sarcoma.[3] Pazopanib also appears effective in the treatment of non-small cell lung carcinoma.[2]


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. "FDA Approves GlaxoSmithKline's Votrient(TM) For Advanced Renal Cell Cancer". Medical News Today. 20 October 2009. Retrieved 8 June 2010. 
  2. 2.0 2.1 "Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer". FierceBiotech. 2008-09-15. Retrieved 2010-08-10. 
  3. Sleijfer, S.; Ray-Coquard, I.; Papai, Z.; Le Cesne, A.; Scurr, M.; Schoffski, P.; Collin, F.; Pandite, L.; Marreaud, S. (2009). "Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients with Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)". Journal of Clinical Oncology. 27 (19): 3126. doi:10.1200/JCO.2008.21.3223. PMID 19451427.  edit